Investigational Drug Information for Aumolertinib
✉ Email this page to a colleague
What is the development status for investigational drug Aumolertinib?
Aumolertinib is an investigational drug.
There have been 16 clinical trials for Aumolertinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2025.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Jiangsu Hansoh Pharmaceutical Co., Ltd., EQRx, Inc., and Sun Yat-sen University.
There are forty US patents protecting this investigational drug and seventy-three international patents.
Summary for Aumolertinib
| US Patents | 40 |
| International Patents | 73 |
| US Patent Applications | 159 |
| WIPO Patent Applications | 180 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2025-10-01) |
| Vendors | 46 |
Recent Clinical Trials for Aumolertinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | PHASE3 |
| A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | Jiangsu Hansoh Pharmaceutical Co., Ltd. | PHASE1 |
| A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | PHASE1 |
Clinical Trial Summary for Aumolertinib
Top disease conditions for Aumolertinib
Top clinical trial sponsors for Aumolertinib
US Patents for Aumolertinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor, preparation method and use thereof | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor, preparation method and use thereof | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | EGFR inhibitor free base or acid salt polycrystalline form, preparation method therefor, and application | Jiangsu Hansoh Pharmaceutical Group Co Ltd , Shanghai Hansoh Biomedical Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | Quinoline derivative for treatment of nasopharyngeal carcinoma | Chia Tai Tianqing Pharmaceutical Group Co Ltd | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors | Array Biopharma Inc | ⤷ Start Trial |
| Aumolertinib | ⤷ Start Trial | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof | Ascentage Pharma Suzhou Co Ltd , Ascentage Pharma Group Co Ltd | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aumolertinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Aumolertinib | Australia | AU2015330506 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | Brazil | BR112017006713 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | Canada | CA2959194 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | China | CN106661000 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | China | CN111170999 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | China | CN111171000 | 2034-10-11 | ⤷ Start Trial |
| Aumolertinib | China | CN111187221 | 2034-10-11 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
